A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet's disease

Tim B.van der Houwen, P. Martin van Hagen, Jasper H. Kappen, Robert W.A.M. Kuijpers, Paul L.A. van Daele, Wim A.van Dik, Jan A.M.van Laar*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

20 Downloads (Pure)

Abstract

Background: Behçet’s disease (BD) is an auto-inflammatory vasculitis characterized by aphthous oro-genital ulcers, inflammatory skin changes and uveitis. Treatment is mainly immunosuppressive. Interestingly, elevated endotheline-1 (ET-1) levels suggest a possible beneficial effect of treatment with an ET-1 receptor antagonist. Objectives: The aim of our study was to investigate the possible beneficial effect of the ET-1 inhibitor bosentan. Methods: We performed a prospective double-blind placebo controlled pilot study into the effect and safety of bosentan in BD patients. Disease activity was measured using the Behçet Disease Current Activity Form. The primary objective of the study was to determine whether bosentan is therapeutically effective in patients with BD. Secondary endpoints were safety, tapering of medication and the effect of bosentan on possible disease activity markers such as ET-1, circulating endothelial cells (CECs), soluble interleukin-2 receptor (sIL2R) and cytokine levels. Results: Ten patients were randomized to either bosentan or placebo. Overall, no effect on disease activity was observed, although one patient responded clinically and continued treatment after the study period. Despite one SAE, bosentan seems safe to use. No effect on tapering of medication, CECs, sIL2R and cytokine levels was found. In the bosentan group, ET-1 levels were elevated during the treatment period, with no correlation with disease activity. Conclusions: Although this is a small pilot study, bosentan appears to be safe in BD patients. One patient had a durable and significant clinical response. Our observations should be confirmed and extended in a larger patient cohort to be of significant impact in the treatment options for BD.

Original languageEnglish
Pages (from-to)435-441
Number of pages7
JournalAsian Pacific Journal of Allergy and Immunology
Volume40
Issue number4
DOIs
Publication statusPublished - 1 Dec 2022

Bibliographical note

Publisher Copyright:
© 2022, Allergy and Immunology Society of Thailand. All rights reserved.

Fingerprint

Dive into the research topics of 'A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet's disease'. Together they form a unique fingerprint.

Cite this